These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38597264)

  • 1. Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.
    Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
    J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy.
    Mittal P; Singh S; Sinha R; Shrivastava A; Singh A; Singh IK
    Int J Biol Macromol; 2021 Sep; 187():999-1018. PubMed ID: 34339789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.
    Bolomsky A; Vogler M; Köse MC; Heckman CA; Ehx G; Ludwig H; Caers J
    J Hematol Oncol; 2020 Dec; 13(1):173. PubMed ID: 33308268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MCL-1 inhibitors - where are we now (2019)?
    Fletcher S
    Expert Opin Ther Pat; 2019 Nov; 29(11):909-919. PubMed ID: 31566022
    [No Abstract]   [Full Text] [Related]  

  • 5. Mcl-1 as a "barrier" in cancer treatment: Can we target it now?
    Pervushin NV; Senichkin VV; Zhivotovsky B; Kopeina GS
    Int Rev Cell Mol Biol; 2020; 351():23-55. PubMed ID: 32247581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Mcl-1 inhibitors for cancer therapy.
    Negi A; Murphy PV
    Eur J Med Chem; 2021 Jan; 210():113038. PubMed ID: 33333396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting MCL-1 in cancer: current status and perspectives.
    Wang H; Guo M; Wei H; Chen Y
    J Hematol Oncol; 2021 Apr; 14(1):67. PubMed ID: 33883020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy.
    Zhu PJ; Yu ZZ; You QD; Jiang ZY
    Drug Discov Today; 2020 Oct; 25(10):1873-1882. PubMed ID: 32771436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors.
    Wan Y; Wang J; Sun F; Chen M; Hou X; Fang H
    Bioorg Med Chem; 2015 Dec; 23(24):7685-93. PubMed ID: 26620718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the development of Mcl-1 inhibitors for cancer therapy.
    Hird AW; Tron AE
    Pharmacol Ther; 2019 Jun; 198():59-67. PubMed ID: 30790641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule Mcl-1 inhibitors for the treatment of cancer.
    Belmar J; Fesik SW
    Pharmacol Ther; 2015 Jan; 145():76-84. PubMed ID: 25172548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy.
    Yamaguchi R; Lartigue L; Perkins G
    Pharmacol Ther; 2019 Mar; 195():13-20. PubMed ID: 30347215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
    Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
    Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein.
    Abid M; Sonawane YA; Contreras JI; Rana S; Natarajan A
    Curr Med Chem; 2017; 24(40):4488-4514. PubMed ID: 28901269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors.
    Lee T; Bian Z; Zhao B; Hogdal LJ; Sensintaffar JL; Goodwin CM; Belmar J; Shaw S; Tarr JC; Veerasamy N; Matulis SM; Koss B; Fischer MA; Arnold AL; Camper DV; Browning CF; Rossanese OW; Budhraja A; Opferman J; Boise LH; Savona MR; Letai A; Olejniczak ET; Fesik SW
    FEBS Lett; 2017 Jan; 591(1):240-251. PubMed ID: 27878989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting MCL-1 in hematologic malignancies: Rationale and progress.
    Wei AH; Roberts AW; Spencer A; Rosenberg AS; Siegel D; Walter RB; Caenepeel S; Hughes P; McIver Z; Mezzi K; Morrow PK; Stein A
    Blood Rev; 2020 Nov; 44():100672. PubMed ID: 32204955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Comprehension of Mcl-1: From Gene Structure to Cancer Therapy.
    Senichkin VV; Streletskaia AY; Zhivotovsky B; Kopeina GS
    Trends Cell Biol; 2019 Jul; 29(7):549-562. PubMed ID: 31030977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
    Wan Y; Dai N; Tang Z; Fang H
    Eur J Med Chem; 2018 Feb; 146():471-482. PubMed ID: 29407973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
    Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG
    Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein-Protein Interaction Modulator with the Potential of Treating Hematological Malignancies.
    Romanov-Michailidis F; Hsiao CC; Urner LM; Jerhaoui S; Surkyn M; Miller B; Vos A; Dominguez Blanco M; Bueters R; Vinken P; Bekkers M; Walker D; Pietrak B; Eyckmans W; Dores-Sousa JL; Joo Koo S; Lento W; Bauser M; Philippar U; Rombouts FJR
    J Med Chem; 2023 May; 66(9):6122-6148. PubMed ID: 37114951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.